Parenteral Drugs (India) (NSE:PDPL) E10: ₹-32.41 (As of Mar. 2022)


NSE:PDPL Parenteral Drugs (India) Ltd NSE:PDPL
4 GF Score
Price ₹2.90
View Full Analysis

What is Parenteral Drugs (India) E10?

Parenteral Drugs (India) NSE:PDPL 4 E10 is ₹-32.41 as of Mar. 2022. GuruFocus rates NSE:PDPL with a GF Score™ of 4/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Parenteral Drugs (India)'s adjusted earnings per share data for the three months ended in Mar. 2022 was ₹7.987. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹-32.41 for the trailing ten years ended in Mar. 2022.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-26), Parenteral Drugs (India)'s current stock price is ₹2.90. Parenteral Drugs (India)'s E10 for the quarter that ended in Mar. 2022 was ₹-32.41. Parenteral Drugs (India)'s Shiller PE Ratio of today is .


Parenteral Drugs (India)  (NSE:PDPL) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Parenteral Drugs (India) E10 Related Terms


Parenteral Drugs (India) E10 Historical Data

* Premium members only.

The historical data trend for Parenteral Drugs (India)'s E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) E10 Chart

Parenteral Drugs (India) Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -24.41 -37.95 -43.34 -32.41

Parenteral Drugs (India) Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.34 -41.12 -47.76 -33.96 -32.41

NSE:PDPL vs ZTS, CTLT, VTRS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Parenteral Drugs (India)'s Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parenteral Drugs (India) Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parenteral Drugs (India)'s Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Parenteral Drugs (India)'s Shiller PE Ratio falls into.


NSE:PDPL
4GF Score
Parenteral Drugs (India) Ltd NSE:PDPL
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parenteral Drugs (India) E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Parenteral Drugs (India)'s adjusted earnings per share data for the three months ended in Mar. 2022 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2022 (Change)*Current CPI (Mar. 2022)
=7.987/138.8218*138.8218
=7.987

Current CPI (Mar. 2022) = 138.8218.

Parenteral Drugs (India) Quarterly Data

per share eps CPI Adj_EPS
201206 -11.660 79.567 -20.344
201209 -7.710 82.244 -13.014
201212 -10.090 83.774 -16.720
201303 -12.230 85.687 -19.814
201306 19.640 88.365 30.855
201309 -5.310 91.042 -8.097
201312 -6.630 91.425 -10.067
201403 -20.950 91.425 -31.811
201406 -6.870 94.103 -10.135
201409 -6.900 96.780 -9.897
201412 -1.860 96.780 -2.668
201503 -7.060 97.163 -10.087
201506 -5.780 99.841 -8.037
201509 -4.880 101.753 -6.658
201512 -14.360 102.901 -19.373
201603 -14.190 102.518 -19.215
201606 -8.460 105.961 -11.084
201609 -7.850 105.961 -10.284
201612 -9.880 105.196 -13.038
201703 -13.700 105.196 -18.079
201706 -10.660 107.109 -13.816
201709 -10.150 109.021 -12.924
201712 -12.210 109.404 -15.493
201803 -4.690 109.786 -5.930
201806 -8.240 111.317 -10.276
201809 -9.010 115.142 -10.863
201812 -8.470 115.142 -10.212
201903 -24.130 118.202 -28.339
201906 -9.290 120.880 -10.669
201909 -9.496 123.175 -10.702
201912 -8.766 126.235 -9.640
202003 -10.710 124.705 -11.922
202006 -10.810 127.000 -11.816
202009 -11.294 130.118 -12.049
202012 -10.388 130.889 -11.018
202103 -8.333 131.771 -8.779
202106 -10.740 134.084 -11.119
202109 -11.273 135.847 -11.520
202112 -11.579 138.161 -11.634
202203 7.987 138.822 7.987

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹-32.41 mean?
Parenteral Drugs (India) (NSE:PDPL) has a E10 of ₹-32.41 as of Mar. 2022. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s E10 too high?
Parenteral Drugs (India)'s current E10 is ₹-32.41. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s E10 compare to ZTS and CTLT?
Parenteral Drugs (India)'s E10 of ₹-32.41 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Parenteral Drugs (India) and its competitors. Parenteral Drugs (India)'s current E10 is ₹-32.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current E10 of ₹-32.41. The current E10 is ₹-32.41. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current E10 is ₹-32.41 as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parenteral Drugs (India) Business Description

Address Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score

Get the complete analysis for NSE:PDPL

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90
Price